Show simple item record

dc.contributor.authorDickerson, Erin B.en_US
dc.contributor.authorBlackburn, William H.en_US
dc.contributor.authorKapa, Laura B.en_US
dc.contributor.authorLyon, L. Andrewen_US
dc.contributor.authorMcDonald, John F.en_US
dc.date.accessioned2010-03-24T20:19:30Z
dc.date.available2010-03-24T20:19:30Z
dc.date.issued2010-01-11
dc.identifier.citationErin B. Dickerson, William H. Blackburn, Michael H. Smith, Laura B. Kapa, L. Andrew Lyon, and John F. McDonald, "Chemosensitization of cancer cells by siRNA using targeted nanogel delivery," BMC Cancer 2010, 10:10.en
dc.identifier.issn1471-2107
dc.identifier.urihttp://hdl.handle.net/1853/32469
dc.description© 2010 Dickerson et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1471-2407/10/10en
dc.descriptionDOI: 10.1186/1471-2407-10-10
dc.description.abstractBackground. Chemoresistance is a major obstacle in cancer treatment. Targeted therapies that enhance cancer cell sensitivity to chemotherapeutic agents have the potential to increase drug efficacy while reducing toxic effects on untargeted cells. Targeted cancer therapy by RNA interference (RNAi) is a relatively new approach that can be used to reversibly silence genes in vivo by selectively targeting genes such as the epidermal growth factor receptor (EGFR), which has been shown to increase the sensitivity of cancer cells to taxane chemotherapy. However, delivery represents the main hurdle for the broad development of RNAi therapeutics. Methods. We report here the use of core/shell hydrogel nanoparticles (nanogels) functionalized with peptides that specially target the EphA2 receptor to deliver small interfering RNAs (siRNAs) targeting EGFR. Expression of EGFR was determined by immunoblotting, and the effect of decreased EGFR expression on chemosensitization of ovarian cancer cells after siRNA delivery was investigated. Results. Treatment of EphA2 positive Hey cells with siRNA-loaded, peptide-targeted nanogels decreased EGFR expression levels and significantly increased the sensitivity of this cell line to docetaxel (P < 0.05). Nanogel treatment of SK-OV-3 cells, which are negative for EphA2 expression, failed to reduce EGFR levels and did not increase docetaxel sensitivity (P > 0.05).en
dc.language.isoen_USen
dc.publisherGeorgia Institute of Technologyen
dc.subjectChemoresistanceen
dc.subjectsiRNAen
dc.subjectTargeted delivery of siRNAsen
dc.subjectNanogelsen
dc.subjectCancer treatmenten
dc.titleChemosensitization of cancer cells by siRNA using targeted nanogel deliveryen
dc.typeArticleen
dc.contributor.corporatenameGeorgia Institute of Technology. School of Biologyen_US
dc.contributor.corporatenameGeorgia Institute of Technology. Institute for Bioengineering and Bioscienceen_US
dc.contributor.corporatenameGeorgia Institute of Technology. Ovarian Cancer Instituteen_US
dc.contributor.corporatenameGeorgia Institute of Technology. School of Chemistry and Biochemistryen_US
dc.contributor.corporatenameUniversity of Minnesota. Dept. of Veterinary Clinical Sciencesen_US
dc.contributor.corporatenameJohns Hopkins University. Dept. of Cellular and Molecular Medicineen_US
dc.publisher.originalBioMed Central
dc.identifier.doi10.1186/1471-2407-10-10


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record